Entrada Therapeutics holder sells 259,837 shares

MPM BioVentures-affiliated ten percent owners reported open-market sales totaling 259,837 TRDA shares over three days while retaining large fund holdings.

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. (TRDA) had common stock sales reported by investment funds affiliated with MPM BioVentures, which are ten percent owners. On September 4, 2026, affiliated funds sold 38,500 shares at a weighted average price of $7.11 per share, with individual sale prices ranging from $7.01 to $7.16. On September 8, 2026, they sold 192,500 shares at a weighted average price of $7.41 per share, with sale prices between $6.97 and $7.70. On September 9, 2026, they sold an additional 28,837 shares at a weighted average price of $7.13, with sale prices between $7.02 and $7.54. After the last reported sale, the funds continued to hold large positions, including 1,764,167 shares held by MPM BioVentures 2014, L.P. and 1,810,592 shares held by MPM BioVentures 2018, L.P. The reporting persons state that each of them disclaims beneficial ownership of the securities except to the extent of their respective pecuniary interest and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 259,837 shares

Net Sell 3 txns

Insider MPM BIOVENTURES 2018, L.P., MPM BioVentures 2018 LLC, MPM BioVentures 2018 GP LLC

Role 10% Owner | 10% Owner | 10% Owner

Sold 259,837 shs ($1.91M)

Type	Security	Shares	Price	Value
Sale	Common Stock F8, F9, F4, F10	28,837	$7.13	$206K
Sale	Common Stock F5, F6, F4, F7	192,500	$7.41	$1.43M
Sale	Common Stock F1, F2, F3, F4	38,500	$7.11	$274K

Holdings After Transaction: Common Stock — 3,885,115 shares (Indirect, See Footnote)

Footnotes (10)

1. F1. The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
2. F2. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
3. F3. The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018.
4. F4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
5. F5. The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018.
6. F6. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
7. F7. The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.
8. F8. The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018.
9. F9. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
10. F10. The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.

Key Figures

Shares sold September 4, 2026: 38,500 shares Shares sold September 8, 2026: 192,500 shares Shares sold September 9, 2026: 28,837 shares +5 more

8 metrics

Shares sold September 4, 2026 38,500 shares Open-market sales of Entrada Therapeutics common stock by affiliated MPM funds

Shares sold September 8, 2026 192,500 shares Open-market sales of Entrada Therapeutics common stock by affiliated MPM funds

Shares sold September 9, 2026 28,837 shares Open-market sales of Entrada Therapeutics common stock by affiliated MPM funds

Total shares sold across all reported dates 259,837 shares Net reported sales by MPM BioVentures-affiliated reporting persons

Weighted average price September 4, 2026 $7.11 per share Within a sale price range of $7.01 to $7.16 per share

Weighted average price September 8, 2026 $7.41 per share Within a sale price range of $6.97 to $7.70 per share

Post-sale holding by MPM BioVentures 2014, L.P. 1,764,167 shares Shares of Entrada Therapeutics common stock held after the latest reported transaction

Post-sale holding by MPM BioVentures 2018, L.P. 1,810,592 shares Shares of Entrada Therapeutics common stock held after the latest reported transaction

Key Terms

weighted average sale price, beneficial ownership, pecuniary interest

3 terms

weighted average sale price financial

"Price represents the weighted average sale price of the shares sold."

beneficial ownership regulatory

"Each Reporting Person disclaims beneficial ownership of the securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of his or its respective pecuniary interest therein."

FAQ

What did MPM BioVentures-related holders report selling of TRDA stock?

Affiliated MPM BioVentures funds reported three open-market sales of Entrada Therapeutics (TRDA) common stock totaling 259,837 shares from September 4 to September 9, 2026, at weighted average prices between about $7.11 and $7.41 per share.

On what dates were TRDA shares sold by the MPM BioVentures funds?

Reported sales occurred on September 4, 2026, September 8, 2026, and September 9, 2026, with each date representing a separate group of transactions in Entrada Therapeutics common stock by MPM BioVentures-affiliated funds.

How many TRDA shares did the MPM BioVentures funds sell on each date?

The funds sold 38,500 shares on September 4, 2026, 192,500 shares on September 8, 2026, and 28,837 shares on September 9, 2026, for a total of 259,837 shares of Entrada Therapeutics common stock.

What prices did the MPM BioVentures funds receive for the TRDA share sales?

The reported weighted average sale prices were $7.11 per share on September 4, 2026, $7.41 per share on September 8, 2026, and $7.13 per share on September 9, 2026, each within stated intraday price ranges around those averages.

Do the MPM BioVentures reporting persons still hold TRDA shares after these sales?

Yes. After the latest reported sale, the filing states that affiliated funds still held large positions, including 1,764,167 shares by MPM BioVentures 2014, L.P. and 1,810,592 shares by MPM BioVentures 2018, L.P., among other fund holdings.

Did the TRDA insider sales occur under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported for these transactions, and it does not describe the sales as being executed under a pre-arranged trading plan.

How do the MPM BioVentures reporting persons describe their beneficial ownership of TRDA?

They state that each reporting person disclaims beneficial ownership of the Entrada Therapeutics securities reported, except to the extent of his or its respective pecuniary interest in those securities held through the various MPM BioVentures funds and entities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 07:24 PM Accepted by SEC EDGAR 09/09/2026 - 07:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MPM BIOVENTURES 2018, L.P.

(Last) (First) (Middle)

C/O MPM BIOIMPACT

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2026		S		38,500(1)	D	$7.11(2)	4,106,452	I	See Footnote(3)(4)
Common Stock	09/08/2026		S		192,500(5)	D	$7.41(6)	3,913,952	I	See Footnote(4)(7)
Common Stock	09/09/2026		S		28,837(8)	D	$7.13(9)	3,885,115	I	See Footnote(4)(10)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

MPM BIOVENTURES 2018, L.P.

(Last) (First) (Middle)

C/O MPM BIOIMPACT

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

MPM BioVentures 2018 LLC

(Last) (First) (Middle)

C/O MPM CAPITAL BIOIMPACT

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

MPM BioVentures 2018 GP LLC

(Last) (First) (Middle)

C/O MPM BIOIMPACT

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.

2. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

3. The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018.

4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

5. The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018.

6. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

7. The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.

8. The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018.

9. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

10. The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.

Remarks:

See Form 4 for MPM BioVentures 2014, L.P for additional members of this joint filing.

	/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC	09/09/2026
	/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC	09/09/2026
	/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018, L.P.	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)